161 related articles for article (PubMed ID: 18586363)
21. Use of the mice passive protection test to evaluate the humoral response in goats vaccinated with Sterne 34F2 live spore vaccine.
Phaswana PH; Ndumnego OC; Koehler SM; Beyer W; Crafford JE; van Heerden H
Vet Res; 2017 Sep; 48(1):46. PubMed ID: 28882176
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of body mass index, pre-vaccination serum progesterone levels and anti-anthrax protective antigen immunoglobulin G on injection site adverse events following anthrax vaccination in women.
Zhang Y; Martin SW; Rose CE; Biagini RE; Franzke LH; Smith JP; Sammons DL; Robertson SA; McNeil MM
Pharmacoepidemiol Drug Saf; 2008 Nov; 17(11):1060-7. PubMed ID: 18781705
[TBL] [Abstract][Full Text] [Related]
23. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice.
Lee JS; Groebner JL; Hadjipanayis AG; Negley DL; Schmaljohn AL; Welkos SL; Smith LA; Smith JF
Vaccine; 2006 Nov; 24(47-48):6886-92. PubMed ID: 16828936
[TBL] [Abstract][Full Text] [Related]
24. Development of an in vitro-based potency assay for anthrax vaccine.
Little SF; Webster WM; Ivins BE; Fellows PF; Norris SL; Andrews GP
Vaccine; 2004 Jul; 22(21-22):2843-52. PubMed ID: 15246620
[TBL] [Abstract][Full Text] [Related]
25. The impact of incomplete vaccination schedules on the magnitude and duration of protective antigen-specific IgG responses in recipients of the US licensed anthrax vaccine.
Lininger LA; Cullum ME; Lyles MB; Bienek DR
Vaccine; 2007 Feb; 25(9):1619-25. PubMed ID: 17150286
[TBL] [Abstract][Full Text] [Related]
26. Passive immunotherapy for anthrax toxin mediated by an adenovirus expressing an anti-protective antigen single-chain antibody.
Kasuya K; Boyer JL; Tan Y; Alipui DO; Hackett NR; Crystal RG
Mol Ther; 2005 Feb; 11(2):237-44. PubMed ID: 15668135
[TBL] [Abstract][Full Text] [Related]
27. Topical immunization onto mouse skin using a microemulsion incorporated with an anthrax protective antigen protein-encoding plasmid.
Cui Z; Sloat BR
Int J Pharm; 2006 Jul; 317(2):187-91. PubMed ID: 16730934
[TBL] [Abstract][Full Text] [Related]
28. Potentiation of an anthrax DNA vaccine with electroporation.
Luxembourg A; Hannaman D; Nolan E; Ellefsen B; Nakamura G; Chau L; Tellez O; Little S; Bernard R
Vaccine; 2008 Sep; 26(40):5216-22. PubMed ID: 18462850
[TBL] [Abstract][Full Text] [Related]
29. Nasal immunization with the mixture of PA63, LF, and a PGA conjugate induced strong antibody responses against all three antigens.
Sloat BR; Shaker DS; Le UM; Cui Z
FEMS Immunol Med Microbiol; 2008 Mar; 52(2):169-79. PubMed ID: 18194342
[TBL] [Abstract][Full Text] [Related]
30. Anthrax protective antigen administered by DNA vaccination to distinct subcellular locations potentiates humoral and cellular immune responses.
Midha S; Bhatnagar R
Eur J Immunol; 2009 Jan; 39(1):159-77. PubMed ID: 19130551
[TBL] [Abstract][Full Text] [Related]
31. Effect of aluminum hydroxide adjuvant and formaldehyde in the formulation of rPA anthrax vaccine.
Little SF; Ivins BE; Webster WM; Norris SL; Andrews GP
Vaccine; 2007 Apr; 25(15):2771-7. PubMed ID: 17240008
[TBL] [Abstract][Full Text] [Related]
32. Validation of an anti-PA-ELISA for the potency testing of anthrax vaccine in mice.
Pombo M; Berthold I; Gingrich E; Jaramillo M; Leef M; Sirota L; Hsu H; Arciniega J
Biologicals; 2004 Sep; 32(3):157-63. PubMed ID: 15536047
[TBL] [Abstract][Full Text] [Related]
33. Immune response to two different dosing schedules of the anthrax vaccine precipitated (AVP) vaccine.
Hepburn MJ; Hugh Dyson E; Simpson AJ; Brenneman KE; Bailey N; Wilkinson L; Hornby R; Mateczun AJ; Bell MG; Baillie LW
Vaccine; 2007 Aug; 25(32):6089-97. PubMed ID: 17604880
[TBL] [Abstract][Full Text] [Related]
34. Human monoclonal antibodies generated following vaccination with AVA provide neutralization by blocking furin cleavage but not by preventing oligomerization.
Smith K; Crowe SR; Garman L; Guthridge CJ; Muther JJ; McKee E; Zheng NY; Farris AD; Guthridge JM; Wilson PC; James JA
Vaccine; 2012 Jun; 30(28):4276-83. PubMed ID: 22425791
[TBL] [Abstract][Full Text] [Related]
35. Reproductive toxicity of BioThrax in rabbits.
Franco C; Lewis E; Morseth S; Simon L; Waytes AT
Birth Defects Res B Dev Reprod Toxicol; 2009 Oct; 86(5):370-6. PubMed ID: 19718687
[TBL] [Abstract][Full Text] [Related]
36. CpG oligodeoxynucleotides adsorbed onto polylactide-co-glycolide microparticles improve the immunogenicity and protective activity of the licensed anthrax vaccine.
Xie H; Gursel I; Ivins BE; Singh M; O'Hagan DT; Ulmer JB; Klinman DM
Infect Immun; 2005 Feb; 73(2):828-33. PubMed ID: 15664922
[TBL] [Abstract][Full Text] [Related]
37. Protective antigen and toxin neutralization antibody patterns in anthrax vaccinees undergoing serial plasmapheresis.
Pittman PR; Leitman SF; Oro JG; Norris SL; Marano NM; Ranadive MV; Sink BS; McKee KT
Clin Diagn Lab Immunol; 2005 Jun; 12(6):713-21. PubMed ID: 15939745
[TBL] [Abstract][Full Text] [Related]
38. Correlation between anthrax lethal toxin neutralizing antibody levels and survival in guinea pigs and nonhuman primates vaccinated with the AV7909 anthrax vaccine candidate.
Savransky V; Shearer JD; Gainey MR; Sanford DC; Sivko GS; Stark GV; Li N; Ionin B; Lacy MJ; Skiadopoulos MH
Vaccine; 2017 Sep; 35(37):4952-4959. PubMed ID: 28774566
[TBL] [Abstract][Full Text] [Related]
39. Cross-species prediction of human survival probabilities for accelerated anthrax vaccine absorbed (AVA) regimens and the potential for vaccine and antibiotic dose sparing.
Stark GV; Sivko GS; VanRaden M; Schiffer J; Taylor KL; Hewitt JA; Quinn CP; Nuzum EO
Vaccine; 2016 Dec; 34(51):6512-6517. PubMed ID: 27558619
[TBL] [Abstract][Full Text] [Related]
40. Catalytically inactive anthrax toxin(s) are potential prophylactic agents.
Gupta M; Alam S; Bhatnagar R
Vaccine; 2007 Dec; 25(50):8410-9. PubMed ID: 17980467
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
